Ignite Creation Date:
2024-05-06 @ 3:18 AM
Last Modification Date:
2024-10-26 @ 11:31 AM
Study NCT ID:
NCT02258321
Status:
COMPLETED
Last Update Posted:
2015-01-22
First Post:
2014-10-02
Brief Title:
Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations
Sponsor:
Presidio Pharmaceuticals Inc
Organization:
Presidio Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 1 Open-Label Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers
Status:
COMPLETED
Status Verified Date:
2015-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will compare the blood levels of PPI-668 resulting from two different formulations - the current capsule and a new tablet T003
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None